Summary
Other Scenarios:
- MYL - GSK
- MYL - DNA
- GSK - PDLI
- DNA - PDLI
| Buyer: | Mylan Inc. (MYL) | Last Price: | 9.31 | Market Cap.: | 2.84B |
|---|---|---|---|---|---|
| Target: | PDL BioPharma Inc. (PDLI) | Last Price: | 9.40 | Market Cap.: | 1.12B |
Lines of Business Summary:
- Mylan Inc. (MYL) competes in 1 industry and 271 product/service groups
- PDL BioPharma Inc. (PDLI) competes in 1 industry and 12 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Mylan Inc. (MYL) has 1 and PDL BioPharma Inc. (PDLI) has 0 suppliers that rely on a material % of their business. They share 0 in common.
- Mylan Inc. (MYL) has 0 and PDL BioPharma Inc. (PDLI) has 2 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
844 |
Biopharmaceuticals |
|
|
368 |
|
Medical Devices |
|
225 | |
|
Outsourced Services |
|
|
48 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 233)
|
Target (Total: 8)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 3)
|
Target (Total: 2)
|
Buyer (Total: 4)
|
Target (Total: 12)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 12,000 | 887 |
| Revenue Per Employee | 553,799.9 | 348,577.5 |
| Total Revenue | 1,656.8 | 77.3 |
| Total Expenses | 1,096.0 | 64.3 |
Other Revenue
|
465.8 | 0.0 |
|
Cost of Revenue
|
745.7 | 0.0 |
|
SG&A Expense
|
275.6 | 18.5 |
|
Research & Development
|
74.7 | 44.7 |
|
Other Operating Expense
|
0.0 | 0.0 |
|
Operating Income
|
560.8 | 13.1 |
|
Unusual Income
|
0.0 | 1.0 |
|
LT Debt to Capital
|
64.69 | 88.93 |
|
Fwd P/E
|
15.03 | 12.78 |
|
Fwd P/Rev
|
0.64 | 3.62 |
| Book Value | 2,977.9 | 66.4 |
|
Curr Portion of LTD/Cap Lease
|
111.3 | 0.8 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
Mylan Inc. (Mylan), formerly Mylan Laboratories Inc., and its subsidiaries comprise a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients (API). Through Matrix Laboratories Limited (Matrix), an company in which Mylan has a 71.5% controlling interest, it manufactures and supplies API for its own products and pipeline, as well as for third parties. Mylan has three segments: the Generics Segment, the Matrix Segment and the Specialty Segment. Its generic pharmaceutical business is conducted primarily in the United States and Canada, Europe, Middle East and Africa, and Australia, Japan and New Zealand. Its specialty pharmaceutical business is conducted by Dey. Its API business is conducted principally through its majority owned subsidiary, Matrix. In June 2008, the Company acquired Merck KGaA's Central & Eastern Europe (CEE) generics businesses.
Target
PDL BioPharma Inc. is a biopharmaceutical company focused on the discovery and development of novel antibodies in oncology and immunologic diseases. It receives royalties and other revenues through licensing agreements with various biotechnology and pharmaceutical companies based on its antibody humanization technology platform. These licensing agreements have contributed to the development by the Company?s licensees of nine marketed products. The Company has several investigational compounds in clinical development for severe or life-threatening diseases, two of which it is developing in collaboration with Biogen Idec MA, Inc. (Biogen Idec). Its products include Daclizumab, Volociximab, HuLuc63, PDL192 and Nuvion. In March 2008, the Company closed the sale of the Cardiovascular Assets, which included Cardene, to EKR Therapeutics, Inc (EKR). However, the Company continues to perform development work for new formulations and presentations of Cardene pursuant to an agreement with EKR.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
39.92 | 100 |
|
Operating Margin %
|
-19.74 | 23.28 |
|
Quick Ratio
|
1.07 | 8.11 |
|
Current Ratio
|
1.88 | 8.34 |
|
Coverage Ratio
|
0.4 | 0.02 |
| Total Assets | 11,024.3 | 718.2 |
| Return on Equity % | -51.9 | 98.81 |
| Return on Assets % | -14.02 | 9.13 |
|
Cash+ ST Inv. Per Share
|
1.54 | 3.63 |
| Total Debt | 5,744.2 | 533.8 |
| Total Debt to Equity % | 192.83 | 804.19 |
| Total Debt to Tangible Equity % | n/a | 911.61 |
|
Debt to Asset %
|
52.11 | 74.32 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Systemic |
|
|
|
Anaphylactic Shock |
|
|
|
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that treat allergic shock by stimulating alpha and beta adrenergic receptors.
Buyer Products:
|
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Buyer Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat chest pains by acting on blood vessels to lower blood pressure.
Buyer Products:
|
|
|
|
Arrhythmia |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of water, but not potassium in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat the ineffective pumping of the heart by preventing the entry of sodium or potassium into heart muscle cells.
Buyer Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Buyer Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Agonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Buyer Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Buyer Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Buyer Products:
|
|
|
|
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water, but not potassium in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Buyer Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Hypotension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat low blood pressure by stimulating alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Buyer Products:
|
|
|
|
Tremors |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that prevent or treat involuntary trembling by blocking the beta adrenergic receptors in muscle tissue.
Buyer Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Antibacterial Agents |
|
|
|
Tetracyclines
Therapeutics that treat acne caused by bacterial infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.
Buyer Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Actinic Keratoses |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat actinic keratoses by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Chronic Urticaria |
|
|
|
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a slow growing, chronic inflammatory skin disorder characterized by dry, scaling patches by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
|
Ulcers |
|
|
|
Pressure |
|
|
|
Debriding Agents
Therapeutics that treat a local excavation on the surface of tissue caused by sustained pressure and friction by removing dead skin cells and foreign material from the wound.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Acid Indigestion/Heartburn |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Buyer Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat or prevent nausea and vomiting by blocking the action of dopamine.
Buyer Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Buyer Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Impacted Bowels |
|
|
|
Hyperosmotic Agents
Therapeutics that treat constipation by causing fluid overload, which in turn induces liquid stool within a short period of time.
Buyer Products:
|
|
|
|
Diarrhea |
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Buyer Products:
|
|
|
|
Antiperistaltic Agents/Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the intestines as well as reducing the surface tension of gas present in the bowels.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat ulcerative colitis through modulation of immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Irritable Bowel Syndrome (IBS) |
|
|
|
Anticholinergic Agents
Therapeutics that treat irritable bowel syndrome by decreasing the liver's cholesterol synthesis and secretion.
Buyer Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that prevent edema by excretion of water, but not potassium, in the urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Adrenal Gland Disorders |
|
|
|
Primary Aldosteronism |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat aldosteronism by excretion of water, but not potassium, in the urine.
Buyer Products:
|
|
|
|
Diabetes |
|
|
|
Induced Complications |
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat hypertension by regulating the blood vessel dilation.
Buyer Products:
|
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Buyer Products:
|
|
|
|
Biguanides/Insulin Stimulating Agents
Therapeutics that control high blood sugar by stimulating the release of insulin as well as decreasing the production of glucose in the liver.
Buyer Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Buyer Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.
Buyer Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Estrogens
Therapeutics that treat hormonal disorders by providing estrogen.
Buyer Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Buyer Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys and prevent the precipitation of urate in the joint.
Buyer Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Pituitary Gland Disorders |
|
|
|
Acromegaly |
|
|
|
Dopamine Receptor Agonists
Therapeutics that stimulate the dopamine receptor.
Buyer Products:
|
|
|
|
Hyperprolactenemia |
|
|
|
Dopamine Receptor Agonists
Products that stimulate the dopamine receptor.
Buyer Products:
|
|
|
|
Pituitary Hyperthyroidism (TSH-Induced) |
|
|
|
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Hypoestrogenism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Hypogonadism |
|
|
|
Female |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Buyer Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that are mixture of two female sex hormones that are important for the development of the female reproductive system.
Buyer Products:
|
|
|
|
Thyroid Gland Disorders |
|
|
|
Hypothyroidism |
|
|
|
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Buyer Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Buyer Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat hyperuricemia by preventing the conversion of hypoxanthine to uric acid.
Buyer Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat hypokalemia by promoting excretion while inhibiting the removal of potassium.
Buyer Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Buyer Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Buyer Products:
|
|
|
|
Monoclonal Antibodies
Therapeutics that treat ulcerative colitis through modulation of immune pathways implicated in the progression of the disease.
Target Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Discoid (DLE) |
|
|
|
Immunosuppressants
Therapeutics that treat an autoimmune disease characterized by disk-shaped skin plaques by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Systemic (SLE) |
|
|
|
Immunosuppressants
Therapeutics that treat systemic lupus by inhibiting a full immune response.
Buyer Products:
|
|
|
|
Psoriasis |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat a chronic autoimmune disease characterized by thickened skin with silver scales by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
|
Immune Deficiency Disorders |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.
Target Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Oxazolidinones
Therapeutics that treat a wide variety of infections by inhibiting early initiation of bacterial protein synthesis.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Sulfonamides
Therapeutics that treat specific bacterial infections by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Digestive System |
|
|
|
Heliobacter pylori |
|
|
|
Proton Pump Inhibitors
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Otitis Media |
|
|
|
Macrolides
Therapeutics that treat infection and inflammation of the middle ear space and ear drum by inhibiting RNA-dependent bacterial protein synthesis.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Pneumonia |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Respiratory Tract Infections |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Prostatitis |
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Buyer Products:
|
|
|
|
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.
Buyer Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Broad Spectrum |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Onychomycosis (Nail) |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Benzyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Amine Derivatives |
|
|
|
Benzyl
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Amine Derivatives |
|
|
|
Benzyl
Therapeutics that treat fungal infections of the groin and perineum by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Tinea Pedis |
|
|
|
Amine Derivatives |
|
|
|
Benzyl
Therapeutics that treat fungal infections of the feet by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the feet by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Tinea Versicolor |
|
|
|
Amine Derivatives |
|
|
|
Benzyl
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by causing a deficiency in the cell wall.
Buyer Products:
|
|
|
|
Nervous System |
|
|
|
Cryptococcal Meningitis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
|
Esophageal Candidiasis |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Oropharyngeal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Buyer Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Tetracyclines
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Buyer Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.
Buyer Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Buyer Products:
|
|
|
|
RNA Viruses |
|
|
|
Retrovirus |
|
|
|
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) |
|
|
|
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Heterotopic Ossification |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat ossification by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Buyer Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Buyer Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Buyer Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Buyer Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Buyer Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Buyer Products:
|
|
|
|
Disease Modifying Anti-Rheumatic Drugs (DMARD) |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the action of the dihydrofolate enzyme.
Buyer Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Buyer Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Buyer Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat simple partial seizures by preventing the uptake of gamma-aminobutyric acid which prevents nerve activation.
Buyer Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Buyer Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Buyer Products:
|
|
|
|
Sodium Channel Modulators
Therapeutics that treat Grand Mal Seizures by modulating the gates which allow sodium into nerve cells.
Buyer Products:
|
|
|
|
Status Epilepticus |
|
|
|
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.
Buyer Products:
|
|
|
|
Headaches |
|
|
|
Vascular (Migraine) |
|
|
|
Acute Treatments |
|
|
|
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that provide preventative treatments for migraine headaches by inhibiting the uptake of molecules that prevent nerve activation.
Buyer Products:
|
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat spasticity by stimulating the alpha adrenergic receptors.
Buyer Products:
|
|
|
|
Aspartic Receptor Antagonists/Glutamic Receptor Antagonists
Therapeutics that treat Spinal Shock by blocking the receptors for aspartic acid and glutamic acid, both excitatory neurotransmitters.
Buyer Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.
Buyer Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the degradation of neurotransmitters.
Buyer Products:
|
|
|
|
Monotherapy |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Restless Leg Syndrome |
|
|
|
Dopamine Receptor Agonists
Therapeutics that treat Restless Leg Syndrome by stimulating dopamine activity.
Buyer Products:
|
|
|
|
Tourette`s Syndrome |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat the disorder involving uncontrolled verbal outbursts, ticks and facial expressions by blocking dopamine receptors on the neurons.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Buyer Products:
|
|
|
|
Dopamine Receptor Blocking Agents/Tricyclic Antidepressants
Therapeutic combinations that treat anxiety by blocking dopamine receptors as well as increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists/Tricyclic Antidepressants
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid as well as increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat anxiety by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat the disorder involving non-specific emotional distress over real or imagined dangers by increasing the synaptic concentrations of norepinephrine.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat obsessive compulsive disorder by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Depression |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat depression by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Dopamine Receptor Blocking Agents/Tricyclic Antidepressants
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin and by blocking the receptor for dopamine.
Buyer Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists/Tricyclic Antidepressants
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid as well as increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat depression by inhibiting the activity of monoamine oxidase, which degrades neurotransmitters.
Buyer Products:
|
|
|
|
Selective Norepinephrine Reuptake Inhibitors (SNRI)
Therapeutics that treat depression by selectively preventing the removal of norepinephrine, and potentiating neurotransmitter activity in the central nervous system (CNS).
Buyer Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Buyer Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Buyer Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Buyer Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Buyer Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Buyer Products:
|
|
|
|
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.
Buyer Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Narcolepsy |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat narcolepsy by stimulating the adrenergic receptors, which causes nervous system stimulation.
Buyer Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Female Genital Disorders |
|
|
|
Ovarian |
|
|
|
Hypogonadism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
These are female sex hormones.
Buyer Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Buyer Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancers by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
|
Estrogen Synthesis Inhibitors
Therapeutics that treat and manage breast cancers by inhibiting the conversion of adrenal androgens to estrogen in peripheral tissues.
Buyer Products:
|
|
|
|
Metastatic |
|
|
|
Estrogen Receptor Blocking Agents
Therapeutics that treat and manage breast cancer by blocking the uptake of estrogen which has been implicated in causing breast cancer.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.
Buyer Products:
|
|
|
|
Head/Neck Cancer |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the head and neck by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Lymphoid |
|
|
|
Acute |
|
|
|
Lymphoblastic |
|
|
|
Antimetabolite Agents |
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Lymphocytic |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of lymphocytic cells by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
|
Purine Analogs
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by interfering with nucleic acid biosynthesis.
Buyer Products:
|
|
|
|
Meningeal |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage neoplasm's of immature immune cells that have spread to the brain by inhibiting an enzyme needed for the synthesis of DNA.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy by preventing the formation of uric acid from xanthine.
Buyer Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Cutaneous T-Cell (CTCL) |
|
|
|
Mycosis Fungoides |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage T-Cell lymphomas of the skin by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy for lymphoma characterized by the presence of Reed-Sternberg cells by preventing the formation of uric acid from xanthine.
Buyer Products:
|
|
|
|
Non-Hodgkin`s Lymphoma (NHL) |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage lymphomas of B-cells and T-cells by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Bone Cancer |
|
|
|
Osteosarcoma |
|
|
|
Localized |
|
|
|
Antimetabolite Agents |
|
|
|
Dihydrofolate Reductase Inhibitors
Therapeutics that treat and manage primary tumors of the bone by inhibiting the production of DNA.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Target Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Small Cell Lung Cancer (SCLC) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Prostate Cancer |
|
|
|
Palliative Agents |
|
|
|
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.
Buyer Products:
|
|
|
|
Testicular Cancer |
|
|
|
Metastatic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage primary tumors of the testes by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Pain Management |
|
|
|
Anesthesia |
|
|
|
General (Systemic) |
|
|
|
Adjunctive |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Buyer Products:
|
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Buyer Products:
|
|
|
|
Non-Narcotics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Buyer Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Buyer Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Buyer Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
5-Lipoxygenase Inhibitors
Therapeutics that inhibit the action of lipoxygenase, thus preventing the formation of certain chemicals responsible for inflammation in the lungs.
Buyer Products:
|
|
|
|
Mast Cell Stabilizers
Therapeutics that treat asthma by inhibiting mast cell degranulation.
Buyer Products:
|
|
|
|
Bronchiectasis |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that treat bronchiectasis by causing dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Beta Adrenergic Receptor Agonists/Anticholinergic Agents
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine and by inhibiting the action of acetylcholine on post-ganglionic nerves as well as smooth muscle.
Buyer Products:
|
|
|
|
Prophylactic Treatments |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Emphysema |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Buyer Products:
|
|
|
|
Respiratory Distress Syndrome (RDS) |
|
|
|
Surfactants
Therapeutics that treat RDS by modifying alveolar surface tension and thereby stabilizing the alveoli.
Buyer Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Buyer Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Complications |
|
|
|
Nausea/Vomiting |
|
|
|
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.
Buyer Products:
|
|
|
|
Neurology |
|
|
|
Seizures |
|
|
|
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.
Buyer Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Buyer Products:
|
|
|
|
Transplantation |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Renal (Kidney) |
|
|
|
Rejection Prophylaxis |
|
|
|
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.
Buyer Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Buyer Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Neurogenic Bladder Disease |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Buyer Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine without striping the body of potassium.
Buyer Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Buyer Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Buyer Products:
|
|
|
|
Diabetic Nephropathy |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat diabetes induced kidney diseases by inhibiting a certain enzyme necessary for regulation of blood pressure.
Buyer Products:
|
|
|
|
Nephrolithiasis/Renal Calculi (Kidney Stones) |
|
|
|
Calcium |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat the formation of kidney stones from calcium deposits by reducing uric acid formation through the inhibition of xanthine oxidase.
Buyer Products:
|
|
|
|
Uric Acid |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the conversion of hypoxanthine to uric acid, thus preventing the deposition of excess uric acid in the kidneys.
Buyer Products:
|
|
|
|
Nephropathic Cystinosis |
|
|
|
Aminothiol Agents
Therapeutics that treat the deposition of cystine crystals in certain cells (reticuloendothelial) in the body by removing the extra cystine from these cells.
Buyer Products:
|
|
|
|
Wound Management |
|
|
|
Burns |
|
|
|
Complications |
|
|
|
Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.
Buyer Products:
|
|
|
|
Medical Devices |
|
|
|
Medical Supplies |
|
|
|
Treatment |
|
|
|
Wound Management/First Aid |
|
|
|
Cleaning/Healing Devices
Devices used to clean and facilitate healing of wounds, such as bandages, dressings, cleansers, anti-infective ointments, sponges, cold compresses and other similar items.
Buyer Products:
|
|
|
|
Outsourced Services |
|
|
|
Development/Manufacturing Services |
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Pharmaceuticals |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Buyer Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Buyer Products:
|
|
|
|
Packaging Services
Outsourced companies that provide packaging services for healthcare products.
Buyer Products:
|
|
|
|
Drug Discovery Services |
|
|
|
Lead Discovery/Validation/Optimization |
|
|
|
Lead Biologics |
|
|
|
Antibodies
Biological lead compounds which have a specific amino acid sequence that only interacts with specific substances to cause an immunological response.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Covidien Ltd.
|
|
n/a | 17,323.033 | 12.73 | 12.32 | 1.75 | 1.77 | 24.47 | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 7,146.791 | 49.80 | 22.36 | 2.56 | 2.53 | 16.90 | |
|
Perrigo Company
|
|
n/a | 2,978.459 | 21.32 | 16.44 | 1.55 | 1.40 | 4.79 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 2,489.670 | 11.30 | 11.87 | 0.99 | 0.98 | 3.90 | |
|
Valeant Pharmaceuticals International
|
|
n/a | 1,704.113 | 14.06 | 61.12 | 2.39 | 2.16 | 8.20 | |
|
Dr. Reddy's Laboratories Limited (ADR)
|
|
n/a | 1,611.227 | 18.41 | 13.24 | 1.46 | 1.17 | n/a | |
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 425.706 | n/a | 113.64 | 0.74 | 0.76 | 1.33 | |
|
Eurand N.V.
|
|
n/a | 368.352 | 23.15 | -31.00 | 3.13 | 2.12 | 4.19 | |
|
Taro Pharmaceutical Industries Ltd.
|
|
n/a | 295.291 | 13.97 | n/a | 0.94 | n/a | 1.58 | |
|
Noven Pharmaceuticals, Inc.
|
|
n/a | 284.823 | 21.33 | 15.49 | 3.00 | 2.71 | 2.93 | |
|
DepoMed, Inc.
|
|
n/a | 80.668 | 4.05 | -2.81 | 2.57 | 2.28 | 1.86 | |
|
Corcept Therapeutics Incorporated
|
|
n/a | 55.723 | n/a | -2.62 | 816.62 | 768.12 | 2.60 | |
|
Lannett Company, Inc.
|
|
n/a | 52.890 | n/a | n/a | 0.66 | n/a | 0.87 | |
|
Spectrum Pharmaceuticals, Inc.
|
|
n/a | 48.346 | n/a | -3.10 | 2.33 | 2.42 | 1.04 | |
|
BioSante Pharmaceuticals, Inc.
|
|
n/a | 43.346 | n/a | -1.96 | 86.51 | n/a | 2.84 | |
|
Chelsea Therapeutics International Ltd.
|
|
n/a | 36.287 | n/a | -1.03 | n/a | 2.77 | 1.09 | |
| Target | |||||||||
|
GlaxoSmithKline plc (ADR)
|
|
n/a | 93,667.975 | 13.40 | 10.67 | 2.68 | 2.39 | 78.84 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Baxter International Inc.
|
|
n/a | 31,107.783 | 16.18 | 15.17 | 2.54 | 2.56 | 5.82 | |
|
Hospira, Inc.
|
|
n/a | 4,280.381 | 14.64 | 11.00 | 1.17 | 1.19 | 17.62 | |
|
Medarex inc.
|
|
n/a | 610.859 | n/a | -13.91 | 11.60 | 12.46 | 1.85 | |
|
Dyax Corp.
|
|
n/a | 207.090 | n/a | -2.65 | 6.87 | 7.62 | n/a | |
|
Sangamo Biosciences, Inc.
|
|
n/a | 133.183 | n/a | -4.41 | 10.99 | 8.82 | 2.47 | |
|
Nuvelo, Inc.
|
|
n/a | 16.099 | n/a | -0.53 | 1.06 | 1.12 | 0.37 | |
|
Boehringer Ingelheim GmbH
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Penwest Pharmaceuticals
|
|
77.00% | 32.935 | n/a | -0.96 | 7.68 | 3.48 | 2.15 | |
|
Cephalon, Inc.
|
|
n/a | 5,133.420 | 20.12 | 15.69 | 2.72 | 2.55 | 14.76 | |
|
PHC, Inc.
|
|
n/a | 24.179 | n/a | 4.76 | 0.49 | n/a | 1.40 | |
| Target | |||||||||
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
|
Highland Distressed Opportunities, Inc
|
|
n/a | 20.374 | n/a | 1.89 | 0.70 | 1.80 | 0.17 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
| Buyer | |||||||||
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Forest Laboratories, Inc.
|
|
n/a | 7,395.873 | 7.69 | 7.32 | 1.87 | 1.83 | 2.20 | |
|
Watson Pharmaceuticals, Inc.
|
|
n/a | 2,489.670 | 11.30 | 11.87 | 0.99 | 0.98 | 3.90 | |
|
Penwest Pharmaceuticals
|
|
n/a | 32.935 | n/a | -0.96 | 7.68 | 3.48 | 2.15 | |
| Target | |||||||||
|
Genentech, Inc.
|
|
68.00% | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
AstraZeneca plc (ADR)
|
|
14.00% | 56,480.158 | 9.23 | 7.88 | 1.79 | 1.75 | n/a | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,605.205 | 14.77 | 14.57 | 3.15 | 2.87 | 5.39 | |
|
Wyeth
|
|
n/a | 47,933.530 | 10.71 | 10.04 | 2.06 | 2.03 | 3.20 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Biogen Idec Inc.
|
|
n/a | 13,712.382 | 17.66 | 13.24 | 3.50 | 3.36 | 5.76 | |
|
Cardinal Health, Inc.
|
|
n/a | 11,701.788 | 9.38 | 8.59 | 0.13 | 0.12 | 7.08 | |
|
McKesson Corporation
|
|
n/a | 9,990.133 | 9.34 | 8.83 | 0.09 | 0.10 | 3.82 | |
|
AmerisourceBergen Corp.
|
|
n/a | 5,164.594 | 20.61 | 10.17 | 0.07 | 0.07 | n/a | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
|
Progenics Pharmaceuticals, Inc.
|
|
n/a | 259.793 | n/a | -7.00 | 3.40 | 2.94 | 2.03 | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
| Buyer | |||||||||
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Forest Laboratories, Inc.
|
|
n/a | 7,395.873 | 7.69 | 7.32 | 1.87 | 1.83 | 2.20 | |
|
Cephalon, Inc.
|
|
n/a | 5,133.420 | 20.12 | 15.69 | 2.72 | 2.55 | 14.76 | |
|
Cornerstone Therapeutics, Inc.
|
|
n/a | 140.831 | n/a | -0.69 | 8.83 | 7.15 | n/a | |
|
Penwest Pharmaceuticals
|
|
n/a | 32.935 | n/a | -0.96 | 7.68 | 3.48 | 2.15 | |
|
Natco Pharma Limited
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Famy Care Ltd
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Roche Holding Ltd. (ADR)
|
|
n/a | 123,605.205 | 14.77 | 14.57 | 3.15 | 2.87 | 5.39 | |
|
Genentech, Inc.
|
|
n/a | 81,785.127 | 26.16 | 24.31 | 6.45 | 6.12 | 6.82 | |
|
Wyeth
|
|
n/a | 47,933.530 | 10.71 | 10.04 | 2.06 | 2.03 | 3.20 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 44,434.739 | 11.35 | 12.69 | 2.14 | 2.03 | 6.45 | |
|
Eli Lilly & Co.
|
|
n/a | 41,396.458 | 17.16 | 8.88 | 2.03 | 1.97 | 3.62 | |
|
Biogen Idec Inc.
|
|
n/a | 13,712.382 | 17.66 | 13.24 | 3.50 | 3.36 | 5.76 | |
|
Cardinal Health, Inc.
|
|
n/a | 11,701.788 | 9.38 | 8.59 | 0.13 | 0.12 | 7.08 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 3,413.400 | n/a | -12.37 | 3.60 | 3.09 | n/a | |
|
Seattle Genetics, Inc.
|
|
n/a | 678.890 | n/a | -8.12 | 20.57 | 19.43 | 6.42 | |
|
Exelixis, Inc.
|
|
n/a | 522.719 | n/a | -2.38 | 4.45 | 3.34 | n/a | |
|
Progenics Pharmaceuticals, Inc.
|
|
n/a | 259.793 | n/a | -7.00 | 3.40 | 2.94 | 2.03 | |
|
Pierre Fabre Medicament
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 4,588.5 | 296.3 | 4,884.8 |
|
Other Revenue
|
501.3 | 0.0 | 501.3 |
| Total Revenue | 5,089.8 | 296.3 | 5,386.1 |
|
Cost of Revenue
|
3,058.1 | 0.0 | 3,058.1 |
|
SG&A Expense
|
1,063.7 | 77.7 | 1,141.4 |
|
Depreciation & Amortization
|
0.0 | 0.0 | 0.0 |
|
Research & Development
|
320.1 | 185.2 | 505.2 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
0.0 | -49.7 | -49.7 |
|
Unusual Expense (Income)
|
1,652.9 | 14.1 | 1,667.0 |
| Total Expenses | 6,094.7 | 227.3 | 6,322.1 |
|
Operating Income
|
-1,004.9 | 69.0 | -935.9 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
-398.2 | 1.2 | -397.0 |
|
Other, Net
|
-23.3 | 0.0 | -23.3 |
| Income Before Taxes | -1,426.4 | 70.2 | -1,356.2 |
| Income Taxes | 119.7 | 4.6 | 124.3 |
| Income After Taxes | -1,546.1 | 65.6 | -1,480.6 |
| Minority Interest (IS) | 2.5 | 0.0 | 2.5 |
|
Net Income - Excl. Xord. Items
|
-1,543.6 | 65.6 | -1,478.0 |
| Discontinued Operations | 0.0 | -53.4 | -53.4 |
|
Net Income - Incl. Xord. Items
|
-1,543.6 | 12.2 | -1,531.4 |
| Preferred Dividends | -120.2 | 0.0 | -120.2 |
|
Income Avail. to Common
|
-1,663.8 | 12.2 | -1,651.7 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
304.4 | 119.3 | 423.7 |
|
Basic EPS - Excl. Xord. Items
|
n/a | 0.55 | -3.49 |
|
Basic EPS - Incl. Xord. Items
|
n/a | 0.10 | -3.61 |
| Full Dilution Adjustment | 34.8 | 2.3 | 37.0 |
| Fully Diluted Shares Outstanding | 458.3 | 152.8 | 611.2 |
|
F.D. EPS - Excl. Xord. Items
|
n/a | 0.43 | -2.42 |
|
F.D. EPS - Incl. Xord. Items
|
n/a | 0.08 | -2.51 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
655.7 | 555.3 | 1,211.0 |
|
ST Investments
|
48.0 | 0.0 | 48.0 |
|
Accounts Receivable
|
1,250.9 | 0.0 | 1,250.9 |
|
Inventory
|
1,119.9 | 0.0 | 1,119.9 |
|
Prepayments and Advances
|
121.8 | 0.0 | 121.8 |
|
Other Current Assets
|
221.7 | 16.4 | 238.0 |
|
Current Assets
|
3,418.0 | 571.7 | 3,989.6 |
|
PPE
|
1,743.5 | 0.0 | 1,743.5 |
|
Accum D&A
|
-692.4 | 0.0 | -692.4 |
|
PPE, Net
|
1,051.1 | 127.3 | 1,178.4 |
| Goodwill & Intangibles | 5,960.6 | 7.8 | 5,968.4 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
594.7 | 11.5 | 606.1 |
| Total Assets | 11,024.3 | 718.2 | 11,742.6 |
| Liabilities | |||
| Accounts Payable | 582.1 | 3.5 | 585.5 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
| Accrued Expenses | 0.0 | 52.1 | 52.1 |
|
ST Debt
|
176.1 | 0.0 | 176.1 |
|
Curr Port of LTD & Cap Lease Oblg
|
111.3 | 0.8 | 112.1 |
| Other (Current) Liabilities | 952.7 | 12.2 | 964.8 |
|
Current Liab.
|
1,822.1 | 68.5 | 1,890.6 |
|
LT Debt
|
5,456.9 | 532.9 | 5,989.8 |
|
Total LT Debt
|
5,456.9 | 532.9 | 5,989.8 |
| Minority Interest (BS) | 29.6 | 0.0 | 29.6 |
| Deferred Taxes | 715.6 | 0.0 | 715.6 |
|
Other LT Liab.
|
21.2 | 50.4 | 71.6 |
|
Total Liabilities
|
8,045.4 | 651.9 | 8,697.2 |
| Shareholders Equity | |||
| Preferred Stock | 1.1 | 0.0 | 1.1 |
| Common Stock | 197.7 | 1.2 | 198.9 |
| Additional Paid in Capital | 3,866.9 | 629.3 | 4,496.1 |
| Retained Earnings | 634.3 | -563.6 | 70.7 |
| Treasure Stock | -1,582.7 | 0.0 | -1,582.7 |
| Other Equity | -138.3 | -0.5 | -138.8 |
|
Total Equity
|
2,979.0 | 66.4 | 3,045.3 |
|
Total Liab. & Equity
|
11,024.3 | 718.2 | 11,742.6 |
|
Shares Outstanding
|
304.7 | 119.3 | 424.0 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | -1,543.6 | 12.2 | -1,531.4 |
| CF Depreciation | 431.4 | 26.2 | 457.6 |
| CF Amortization | 0.0 | 7.2 | 7.2 |
| CF Deferred Taxes | -162.4 | -0.3 | -162.6 |
| Other Non-Cash Items | 1,650.4 | 38.0 | 1,688.4 |
| Change in Working Capital | -47.7 | 33.8 | -13.9 |
| Total Cash From Operating Activities | 328.1 | 117.1 | 445.2 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -154.9 | -15.1 | -170.0 |
| Other Investing Cash Flows | -7,026.9 | 723.1 | -6,303.8 |
| Total Cash From Investing Activities | -7,181.8 | 708.0 | -6,473.8 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | -102.7 | 0.0 | -102.7 |
| Purchase Or Sale of Stock | 2,886.1 | 20.6 | 2,906.7 |
| Purchase and Retirement of Debt | 3,758.8 | -6.1 | 3,752.7 |
| Other Financing Cash Flow | -264.9 | -494.2 | -759.1 |
| Total Cash From Financing Activities | 6,277.3 | -479.8 | 5,797.5 |
| Exchange Rate Effects | 28.4 | 0.0 | 28.4 |
| Net Change in Cash | -548.0 | 345.3 | -202.7 |
| Cash Taxes Paid | 179.1 | 0.2 | 179.3 |
| Cash Interest Paid | 174.0 | 12.4 | 186.5 |